Effectiveness of bisphosphonates on nonvertebral and hip fractures in the first year of therapy: the risedronate and alendronate (REAL) cohort study
about
Updates on mechanism of action and clinical efficacy of risedronate in osteoporosisGreater first year effectiveness drives favorable cost-effectiveness of brand risedronate versus generic or brand alendronate: modeled Canadian analysis.Identification and validation of vertebral compression fractures using administrative claims data.Longitudinal change in clinical fracture incidence after initiation of bisphosphonatesEffect of Sequential Treatment with Bisphosphonates After Teriparatide in Ovariectomized Rats: A Direct Comparison Between Risedronate and Alendronate.Validation of diagnostic codes for subtrochanteric, diaphyseal, and atypical femoral fractures using administrative claims data.Risedronate's efficacy: from randomized clinical trials to real clinical practice.Efficacy of ibandronate: a long term confirmation.Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy.Long-term treatment with bisphosphonates and their safety in postmenopausal osteoporosis.Osteoporosis therapies: evidence from health-care databases and observational population studies.Atypical femoral diaphyseal and subtrochanteric fractures and their association with bisphosphonates.Efficacy and safety of risedronate 150 mg once a month in the treatment of postmenopausal osteoporosisRisedronate's Role in Reducing Hip Fracture in Postmenopausal Women with Established Osteoporosis.Relative effectiveness of osteoporosis drugs for preventing nonvertebral fracture.Evidence of sustained vertebral and nonvertebral antifracture efficacy with ibandronate therapy: a systematic review.Bazedoxifene: the evolving role of third-generation selective estrogen-receptor modulators in the management of postmenopausal osteoporosisContralateral hip fractures and other osteoporosis-related fractures in hip fracture patients: incidence and risk factors. An observational cohort study of 1,229 patients.Clinical role of bisphosphonate therapy.An opportunity for improving osteoporosis treatment in home health careOSTEOPOROSIS DIAGNOSIS AND TREATMENT.Bisphosphonates in the management of postmenopausal osteoporosis--optimizing efficacy in clinical practice.Risk of hip fracture after bisphosphonate discontinuation: implications for a drug holiday.Proximal humeral fracture as a risk factor for subsequent hip fracturesRisedronatE and ALendronate Intervention over Three Years (REALITY): minimal differences in fracture risk reductionEffects of clodronate and alendronate on osteoclast and osteoblast co-cultures on silk-hydroxyapatite films.Effectiveness of antiresorptives for the prevention of nonvertebral low-trauma fractures in a population-based cohort of womenNew dosing options in osteoporosis treatment: clinical evidence on Risedronate 75mg monthly treatment.Role of observational studies in assessing osteoporosis therapies: the REAL study.The effects of bisphosphonates on jaw bone remodeling, tissue properties, and extraction healing.Clinical strategies to address patients' concerns in osteoporosis management with bisphosphonates.Coordinator-based systems for secondary prevention in fragility fracture patients.Individualizing osteoporosis therapy.Time to onset of efficacy in fracture reduction with current anti-osteoporosis treatments.Exploring methods for comparing the real-world effectiveness of treatments for osteoporosis: adjusted direct comparisons versus using patients as their own control.Evaluation of the effect of 4 months of risedronate therapy on femoral strength using femoral strength analysis tools.Risedronate versus alendronate in older patients with osteoporosis at high risk of fracture: an Italian cost-effectiveness analysis.Longitudinal change in hip fracture incidence after starting risedronate or raloxifene: an observational study.Effectiveness of risedronate and alendronate on nonvertebral fractures: an observational study through 2 years of therapy.Bisphosphonate binding affinity affects drug distribution in both intracortical and trabecular bone of rabbits.
P2860
Q26864549-9E7322E7-8293-4FA7-8EB7-701E092B54ACQ33305959-7234757A-472A-4415-94F7-E5E616EBD596Q33395609-754DF3D3-314E-4580-BFA9-D116806A3C5FQ33819111-BE005FB9-D224-49BE-AFEB-D1643BE9E939Q33841863-06112FCA-2DD9-4C5E-8EB6-1A9C2366124BQ33958113-A81119D4-98C5-40D5-95F7-A7D3000ACC08Q33965652-DEDF2441-913A-495A-B094-B3A298AC1CC0Q33965657-5EB7170D-C0BD-4E45-A7A9-94FE85A624A2Q34009569-66580B69-F3F4-4764-8563-BE2CC6018461Q34018048-7CACC07D-6B67-4FBF-9F62-8EE83834D7C2Q34242906-8EBBE0A9-B670-4099-82BB-5E08B43CE199Q34522484-37DBF5B0-FEEA-4AFD-98E5-32F0D9029049Q34658660-7D59059A-8895-47AC-9743-1F54EA1EAB3CQ35678676-B6C4E0B9-0517-430A-87D8-B74F18D72D5AQ35774970-8A856540-E965-47D2-B1FA-D39CDFFD105BQ36056975-F7A003D1-7D55-4772-A1FE-FFE004883B08Q36059535-02598CF8-3F5A-43FE-B578-BAB581F5F2E4Q36105275-34E5A98F-4207-4A5E-AFBF-537DE3663F8CQ36311593-620385DB-6B12-4AB7-95BC-697864C504EBQ36683964-5FBA7A6D-3655-4979-9516-FF3CA90455A4Q36703994-6183F0CF-F9D7-4AD2-AF2A-AA2CBFD421A2Q36897441-A315C9F8-DE52-45E2-BD82-224C7DABF3BEQ36952170-C1CB6DF7-F532-4CB2-A45D-89D0235D4488Q37160081-3B4D40EB-C063-42F5-87E4-FADF8E1AE96CQ37264078-721A3F7B-B4FE-4FD2-B077-CD9AAE4DB7ACQ37392009-D2276BED-F8C8-4C5E-B485-86EE97518BC0Q37401847-200AFFA6-8187-4760-A56D-CCDAF7F59AC3Q37430360-8644C4F7-82FB-452A-9471-9B2D36B44D57Q37430500-3DD77C90-F405-4451-8A3F-F23E23E26EA6Q37832692-DCF35324-9DB3-4979-A02E-11B977EE3EEFQ37862933-C36ECA6B-FACB-4CC5-93F3-737E2C256D63Q37879009-4AC81C93-875F-4652-83F1-455034EF17D6Q37973239-62DBE975-96A7-4AF5-9E21-0CF71AA5FD0BQ38014250-F961BC9D-B6F1-4F0D-B826-398AD7AA0E74Q42108489-98D6E644-DBA0-465D-9DA5-568CA959044FQ43166167-B30A971E-D7DD-4626-9760-EEDB59789951Q43166707-1D59243B-A781-4BFD-ADE8-06DF68B597B4Q44381104-B875924F-9EAB-4239-895C-FB5FD396112EQ44574043-E34C0290-2A64-4ED5-AB25-CC7C2D9D3317Q45997666-5A4D4195-3644-41B2-B770-420E226B19DB
P2860
Effectiveness of bisphosphonates on nonvertebral and hip fractures in the first year of therapy: the risedronate and alendronate (REAL) cohort study
description
2006 nî lūn-bûn
@nan
2006 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Effectiveness of bisphosphonat ...... lendronate (REAL) cohort study
@ast
Effectiveness of bisphosphonat ...... lendronate (REAL) cohort study
@en
type
label
Effectiveness of bisphosphonat ...... lendronate (REAL) cohort study
@ast
Effectiveness of bisphosphonat ...... lendronate (REAL) cohort study
@en
prefLabel
Effectiveness of bisphosphonat ...... lendronate (REAL) cohort study
@ast
Effectiveness of bisphosphonat ...... lendronate (REAL) cohort study
@en
P2093
P2860
P1476
Effectiveness of bisphosphonat ...... lendronate (REAL) cohort study
@en
P2093
P D Delmas
S L Silverman
P2860
P2888
P356
10.1007/S00198-006-0274-Z
P407
P577
2006-11-15T00:00:00Z